<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: OSE</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Fri, 15 Nov 2024 14:04:07 GMT</pubDate>
  <item>
    <title>HydrogenPro (OSE: HYPRO) meets the European Hydrogen Bank regulations</title>
    <pubDate>Fri, 15 Nov 2024 14:04:07 GMT</pubDate>
    <link>https://www.pressen.se/1096900317.html</link>
    <description></description>
    <source>DI</source>
  </item>


  <item>
    <title>Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business</title>
    <pubDate>Thu, 31 Oct 2024 06:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1091109098.html</link>
    <description>Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 123.1 million compared to 141.0 in the corresponding quarter last year.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Navamedic Q2 och H1 2024: Den stabila tillväxten fortsätter och stöds av ett nytt licensavtal</title>
    <pubDate>Fri, 16 Aug 2024 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1063007018.html</link>
    <description>Oslo, 16 augusti 2024 – Under första halvåret 2024 levererade Navamedic ASA (OSE: NAVA), ett nordiskt läkemedelsföretag och leverantör av produkter till sjukhus och apotek, en omsättning på 277,2 miljoner NOK, en ökning med 12,8 procent jämfört med samma period förra året. Justerad EBITDA slutade på 41,1 MNOK, jämfört med 26,3 MNOK 2023. Milstolpsbetalningen på 22,7 MNOK från licensavtalet med Orion Corporation för att marknadsföra och sälja Flexilev® och OraFID® i Europa ingår..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement</title>
    <pubDate>Fri, 16 Aug 2024 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1063007017.html</link>
    <description>Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Navamedic ASA: Broad launch for Eroxon® in Sweden today</title>
    <pubDate>Mon, 06 May 2024 09:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1027905354.html</link>
    <description>Oslo, 6 May 2024 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies has launched Eroxon® in Sweden. Eroxon® is clinically proven and considered a breakthrough in treatment of erectile dysfunction for men and will be the first non-prescription treatment for erectile dysfunction in the Swedish market..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Japanska gummiterminer handlas till den högsta prisnivån på 13 år</title>
    <pubDate>Sun, 17 Mar 2024 15:38:32 GMT</pubDate>
    <link>https://www.pressen.se/1015521087.html</link>
    <description>Japanska gummiterminer steg för den nionde sessionen i rad under fredagen och handlades under dagen på den högsta nivån på 13 år. Viktiga producerande länder har väderproblem.



Osaka Exchange (OSE) gummikontrakt för leverans i augusti slutade upp med 19 yen, eller 5,71 procent, till 352 yen per kg, den högsta stängningen sedan 22 september 2011.</description>
    <source>Råvarumarknaden</source>
  </item>
  <item>
    <title>Navamedic Q4 and full year 2023: A year marked by new records and transformative growth initiatives</title>
    <pubDate>Thu, 15 Feb 2024 07:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1007585493.html</link>
    <description>  Oslo, 15 February 2024 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announced its results for the fourth quarter and for the full year 2023. Revenues for the year was up 34 per cent to NOK 512 million, mainly by organic growth. For the first time all three product categories were above the NOK 100 million mark..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Navamedic ASA: Renewed contract signed with Vitaflo International Limited</title>
    <pubDate>Thu, 21 Dec 2023 16:20:13 GMT</pubDate>
    <link>https://www.pressen.se/995648941.html</link>
    <description>Oslo, 21 December 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo International Limited (Vitaflo International), granting Navamedic the exclusive rights to market and distribute Vitaflo International’s medical nutrition products across the Nordic region for an additional five years..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Smartoptics Group AS (SMOP) – Q3 2023 financial results</title>
    <pubDate>Wed, 08 Nov 2023 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/971722797.html</link>
    <description>Oslo, 8 November 2023 - Smartoptics Group AS (Smartoptics, OSE: SMOP) today reported revenues of USD 13.6 million in the third quarter of 2023 (13.5), and an underlying growth of 13% when excluding 5G related projects.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Navamedic ASA: Record high quarter with above 50 percent growth</title>
    <pubDate>Wed, 01 Nov 2023 07:00:00 GMT</pubDate>
    <link>https://www.pressen.se/966097621.html</link>
    <description>Oslo, 1 November 2023 – Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces its results for the third quarter of 2023. With growth across the company’s three core product areas, Prescription Drugs (RX), Consumer Health and Hospital, year to date, Navamedic has delivered another record quarter. Revenues for the third quarter amounted to NOK 141 million, corresponding to a 51.</description>
    <source>DI</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.046628952026367 s -->